Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.43 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL572043 | 0.88 | SIGMAR1 (0.59) | SIGMAR1ALDH1A1NR2F2RAB9ADRD2 | |
| SCHEMBL25261117 | 0.88 | TIPARP (0.55) | SIGMAR1TIPARP | |
| SCHEMBL15383633 | 0.85 | SIGMAR1 (0.53) | SIGMAR1ALDH1A1NR2F2RAB9ASUV39H2 | |
| SCHEMBL30080558 | 0.85 | TIPARP (0.52) | SIGMAR1ALDH1A1NR2F2RAB9ASUV39H2 | |
| SCHEMBL573370 | 0.83 | HTT (0.48) | ALDH1A1HSD17B10TIPARPPANK3KDM4E | |
| SCHEMBL15383644 | 0.83 | DRD2 (0.46) | SIGMAR1DRD2HDAC6 | |
| SCHEMBL15383639 | 0.82 | DRD2 (0.47) | SIGMAR1DRD2HDAC6 | |
| SCHEMBL13799649 | 0.81 | SIGMAR1 (0.65) | SIGMAR1ALDH1A1NR2F2RAB9ADRD2 | |
| SCHEMBL15383665 | 0.81 | KDM4E (0.61) | SIGMAR1ALDH1A1HSD17B10RAB9AGPR119 | |
| SCHEMBL25268928 | 0.81 | TIPARP (0.52) | SIGMAR1TIPARPKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303497-A1 | DEUTERATED 5-HT1A RECEPTOR AGONISTS | CONRIG PHARMA APS (DK) | 2013-11-14 | — | — | US | disclosed |
| US-20130303497-A1 | DEUTERATED 5-HT1A RECEPTOR AGONISTS | CONRIG PHARMA APS (DK) | 2013-11-14 | — | — | US | disclosed |
| US-20130303497-A1 | DEUTERATED 5-HT1A RECEPTOR AGONISTS | CONRIG PHARMA APS (DK) | 2013-11-14 | — | — | US | disclosed |
| EP-2601187-A1 | DEUTERATED TANDOSPIRONE DERIVATIVES AS 5-HT1A RECEPTOR AGONISTS | Conrig Pharma ApS (DK) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012016569-A1 | DEUTERATED TANDOSPIRONE DERIVATIVES AS 5-HT1A RECEPTOR AGONISTS | CONRIG PHARMA APS (DK) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303497-A1 | DEUTERATED 5-HT1A RECEPTOR AGONISTS | HTR1A, HTR1D, HTR5A | SIGMAR1 112/4885ALDH1A1 620/4885HSD17B10 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.